[November 27, 2015] |
|
Research and Markets: Chemotherapy Induced Neutropenia - Pipeline Review & Analysis H2 2015
Research and Markets (http://www.researchandmarkets.com/research/j84hq9/chemotherapy)
has announced the addition of the "Chemotherapy
Induced Neutropenia - Pipeline Review, H2 2015" report to their
offering.
The report, Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015,
provides an overview of the Chemotherapy Induced Neutropenia's
therapeutic pipeline.
This report provides comprehensive information on the therapeutic
development for Chemotherapy Induced Neutropenia, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases.
Key Topics Covered:
-
Snapshot of the global therapeutic landscape of Chemotherapy Induced
Neutropenia
-
Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
-
Key players involved in the therapeutics development for Chemotherapy
Induced Neutropenia and enlists all their major and minor projects
-
All dormant and discontinued pipeline projects
-
Chemotherapy Induced Neutropenia products under development by
companies and universities/researchinstitutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
Detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis
of target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Benefits of this Report:
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Chemotherapy Induced Neutropenia
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Chemotherapy Induced Neutropenia pipeline depth and focus of
Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Apotex, Inc.
-
Biogenomics Limited
-
Bolder Biotechnology, Inc.
-
Cellerant Therapeutics, Inc.
-
Chong Kun Dang Pharmaceutical Corp.
-
Dr. Reddy's Laboratories Limited
-
Generon (Shanghai) Corporation Ltd.
-
Genexine, Inc.
-
Hanmi Pharmaceuticals, Co. Ltd.
-
Hospira, Inc.
-
Myelo Therapeutics GmbH
-
Octapharma AG
-
Pfenex Inc.
-
Pfizer Inc.
-
PharmaEssentia Corporation
-
Reliance Life Sciences Pvt. Ltd.
-
Richter Gedeon Nyrt.
-
Sandoz International GmbH
-
UAB Profarma
-
USV Limited
-
Welichem Biotech Inc.
For more information visit http://www.researchandmarkets.com/research/j84hq9/chemotherapy
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005404/en/
[ Back To TMCnet.com's Homepage ]
|